Moderna and Merck Announce Melanoma Vaccine Trial Meets Goal; Moderna Shares Jump 20% Premarket

Moderna and Merck announced that their jointly developed melanoma skin cancer vaccine achieved the primary goal in a large clinical trial. In response to the news, Moderna's U. S. premarket shares rose sharply, with gains exceeding 100% at one point, while Merck's premarket shares advanced 5.6%. The two companies have not yet published complete trial data details and will disclose additional information at a later date.